BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1638466)

  • 1. New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
    Oken MM
    Cancer; 1992 Aug; 70(4 Suppl):946-8. PubMed ID: 1638466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Pott C; Wörmann B; Sandford D; Freund M; Engert A; Gassmann W; Holtkamp W; Seufert J
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):28-31. PubMed ID: 8235693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Pawelski S
    Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
    Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-grade malignant non-Hodgkin lymphomas--current status and trends in therapy].
    Hiddemann W
    Ther Umsch; 1996 Feb; 53(2):123-32. PubMed ID: 8629262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma.
    Borden EC
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):14-22. PubMed ID: 7992095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of alpha-interferon in multiple myeloma.
    Peest D
    Pathol Biol (Paris); 1999 Feb; 47(2):172-7. PubMed ID: 10192884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
    Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI
    Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment of follicular and low-grade non-Hodgkin's lymphoma.
    Linch D
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S5-9. PubMed ID: 11508934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
    Alas S; Bonavida B; Emmanouilides C
    Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interferon alpha in the treatment of non-Hodgkin's lymphomas of low malignancy].
    Monnereau A; Soubeyran P; Bonichon F; Eghbali H; Tchen N; Hoerni B
    Bull Cancer; 1998 Oct; 85(10):855-65. PubMed ID: 9835863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Gherlinzoni F; Merla E; Gozzetti A; Tura S
    Haematologica; 1996; 81(2):168-71. PubMed ID: 8641650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
    Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
    Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon-alpha therapy in non-Hodgkin's lymphoma].
    Fridrik MA
    Wien Med Wochenschr; 1993; 143(16-17):429-34. PubMed ID: 8273367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine in low-grade lymphoma.
    Pigaditou A; Rohatiner AZ; Whelan JS; Johnson PW; Ganjoo RK; Rossi A; Norton AJ; Amess J; Lim J; Lister TA
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):24-7. PubMed ID: 8235692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of chronic lymphatic leukemia].
    Adam Z; Vorlícek J; Hejlová N
    Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.